Taken together, these data provide insights into the interplay between ANXA2 and KRT17 in NAFLD, paving the way for understanding molecular mechanisms involved with the disease and developing new therapeutic strategies. This evidence concerns the gene KRT17 and metabolic dysfunction-associated steatotic liver disease.